

STANDARD TREATMENT WORKFLOW (STW)

Psoriasis

Binod K Khaitan¹, Deepika Pandhi², Ananta Khurana³, Dipankar De⁴, Rahul Mahajan⁵, Renu George⁶, Vishal Gupta⁷

¹All India Institute of Medical Sciences, New Delhi; ²University College of Medical Sciences, New Delhi; ³Dr. Ram Manohar Lohia Hospital, New Delhi; ⁴Postgraduate Institute of Medical Education and Research, Chandigarh; ⁵Postgraduate Institute of Medical Education and Research, Chandigarh; ⁶Christian Medical College, Vellore; ⁷All India Institute of Medical Sciences, New Delhi

CORRESPONDING AUTHOR

Dr Binod K Khaitan, Department of Dermatology, All India Institute of Medical Sciences, New Delhi
Email: binodkhaitan@hotmail.com

CITATION

Khaitan BK, Pandhi D, Khurana A, De D, Mahajan R, George R, Gupta V. Psoriasis. Journal of the Epidemiology Foundation of India. 2024;2(1Suppl):S93-S94.

DOI: <https://doi.org/10.56450/JEFI.2024.v2i1Suppl.047>

This work is licensed under a Creative Commons Attribution 4.0 International License.

@The Author(s). 2024 Open Access

DISCLAIMER

This article/STW, was originally published by Indian Council of Medical Research (ICMR) under Standard Treatment Workflow. The reprinting of this article in Journal of the Epidemiology Foundation of India (JEFI) is done with the permission of ICMR. The content of this article is presented as it was published, with no modifications or alterations. The views and opinions expressed in the article are those of the authors and do not necessarily reflect the official policy or position of JEFI or its editorial board. This initiative of JEFI to reprint STW is to disseminate these workflows among Health Care Professionals for wider adoption and guiding path for Patient Care.

JULY 2024



Department of Health Research
Ministry of Health and Family Welfare, Government of India



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
FOUNDED ON 29th JANUARY 1952

Standard Treatment Workflow (STW)

PSORIASIS

ICD-10-L40

*GENERAL PRINCIPLES OF MANAGEMENT

- Establish the diagnosis
- Usually clinical and by bed side tests (Auspitz sign, Grattage test)
- If in doubt, refer to higher centre for evaluation & skin biopsy
- Assess for psoriatic arthritis and metabolic syndrome (obesity, dyslipidemia, diabetes, hypertension)
- Counsel about variable natural course of disease and expected treatment outcome, and lifestyle modifications (including weight reduction, avoidance of smoking and alcohol)
- Assess for requirement of systemic treatment, in addition to topical treatment
- Advise regular use of emollients/ moisturizers. Antihistamines if pruritic
- Avoid Methotrexate and Cyclosporine A in children scheduled for live vaccines
- Rule out tuberculosis, HIV, Hepatitis B and C infections before systemic immunosuppressive treatment
- Pregnancy test-prior to systemic therapy (Acitretin avoided in child bearing age group)
- Systemic steroids should not be given for the treatment of psoriasis, except for generalized pustular psoriasis of pregnancy
- If first-line treatment options fail or are contraindicated, refer to tertiary care center for combination. Baseline investigations to be carried out
- These principles should be used only as a general guide to choose a treatment; final decision should be made on case-to-case basis

TREATMENT OVERVIEW

TOPICAL THERAPY (<5% BODY SURFACE AREA (BSA))

- Moisturizers like white soft paraffin
- Topical corticosteroids, Tacrolimus ointment, Tazarotene, Calcipotriol, Coal tar, Dithranol, Salicylic acid combinations
- **PHOTOTHERAPY (>5% BSA/ PALMOPLANTAR PSORIASIS)**
- Narrow band UVB, Targeted phototherapy, Topical/systemic PUVA or Psoralens with sunlight (PUVAso)
- **SYSTEMIC THERAPY (>5% BSA/ SEVERE RECALCITRANT DISEASE/ PALMOPLANTAR PSORIASIS/ ARTHRITIS)**
- Methotrexate/ Cyclosporine A/ Retinoids-isotretinoin (may be preferred in adolescent girls), Acitretin/ oral antibiotics (guttate psoriasis)/ novel small molecules
- Resistant cases- Biologics

VARIANTS
OF
PSORIASIS

PLAQUE PSORIASIS

GUTTATE PSORIASIS

PALMOPLANTAR PSORIASIS

ERYTHRODERMIC PSORIASIS

PUSTULAR PSORIASIS



Standard Treatment Workflow (STW)

PSORIASIS

ICD-10-L40

*GENERAL PRINCIPLES OF MANAGEMENT

- Establish the diagnosis
 - Usually clinical and by bed side tests (Auspitz sign, Grattage test)
 - If in doubt, refer to higher centre for evaluation & skin biopsy
 - Assess for psoriatic arthritis and metabolic syndrome (obesity, dyslipidemia, diabetes, hypertension)
 - Counsel about variable natural course of disease and expected treatment outcome, and lifestyle modifications (including weight reduction, avoidance of smoking and alcohol)
 - Assess for requirement of systemic treatment, in addition to topical treatment
 - Advise regular use of emollients/ moisturizers. Antihistamines if pruritic
 - Avoid Methotrexate and Cyclosporine A in children scheduled for live vaccines
 - Rule out tuberculosis, HIV, Hepatitis B and C infections before systemic immunosuppressive treatment
 - Pregnancy test-prior to systemic therapy (Acitretin avoided in child bearing age group)
 - Systemic steroids should not be given for the treatment of psoriasis, except for generalized pustular psoriasis of pregnancy
 - If first-line treatment options fail or are contraindicated, refer to tertiary care center for combination. Baseline investigations to be carried out
- These principles should be used only as a general guide to choose a treatment; final decision should be made on case-to-case basis

TREATMENT OVERVIEW

- TOPICAL THERAPY (<5% BODY SURFACE AREA (BSA))**
 - Moisturizers like white soft paraffin
 - Topical corticosteroids, Tacrolimus ointment, Tazarotene, Calcipotriol, Coal tar, Dithranol, Salicylic acid combinations
- PHOTOTHERAPY (>5% BSA/ PALMOPLANTAR PSORIASIS)**
 - Narrow band UVB, Targeted phototherapy, Topical/systemic PUVA or Psoralens with sunlight (PUVASol)
- SYSTEMIC THERAPY (>5% BSA/ SEVERE RECALCITRANT DISEASE/ PALMOPLANTAR PSORIASIS/ ARTHRITIS)**
 - Methotrexate/ Cyclosporine A/ Retinoids-isotretinoin (may be preferred in adolescent girls), Acitretin/ oral antibiotics (guttate psoriasis)/ novel small molecules
 - Resistant cases- Biologics

VARIANTS OF PSORIASIS

PLAQUE PSORIASIS

GUTTATE PSORIASIS

PALMOPLANTAR PSORIASIS

ERYTHRODERMIC PSORIASIS

PUSTULAR PSORIASIS

PLAQUE PSORIASIS

Erythematous plaques with silvery white scales

LIMITED PLAQUE PSORIASIS (< 5%)

- PRIMARY/ SECONDARY LEVEL**
- Face and flexures - 1% Hydrocortisone/ low potency steroid cream OD for 2 weeks
 - Trunk and extremities - Betamethasone cream (or any other potent steroid, preferably with Salicylic acid 3-6%) OD for 2-4 weeks
 - Other topical treatment as listed in treatment overview
- TERTIARY LEVEL**
- Continue with topical therapy
 - If the patient does not respond in 6-8 weeks, try alternate topical agents and/ or systemic therapy or NB UV-B/ PUVA/ PUVASol



GENERALIZED PLAQUE PSORIASIS

REFER TO GENERAL PRINCIPLES OF MANAGEMENT PREFERABLY TO BE MANAGED AT HIGHER CENTRE

- Systemic treatment- refer to treatment overview
- If these fail or are contraindicated, refer to tertiary level for combination or rotational therapy/ novel small molecules/ biologicals
- Continue emollients
- Avoid irritants & prolonged use of topical steroids
- Scalp- Tar based shampoo and topical steroids +/- salicylic acid lotions

GUTTATE PSORIASIS

CLINICAL FEATURES

- Show of numerous erythematous papules < 1 cm on the trunk and extremities
- Seen more commonly in younger patients

TREATMENT

REFER TO GENERAL PRINCIPLES OF MANAGEMENT*

Primary health centre/Level

- Antibiotics for streptococcal infection
- Secondary Level**
- Same as primary level care
 - Psoralen ultraviolet A Solar (PUVASol)

Tertiary Level

- Same as primary level care
- Narrow band UVB
- Refractory cases- consider systemic treatments including novel small molecules



PALMOPLANTAR PSORIASIS

Chronic erythematous well defined plaques symmetrically on palms and soles, and occasional nail involvement to be differentiated from palmo/plantar eczema

REFER TO GENERAL PRINCIPLES OF MANAGEMENT*

PRIMARY HEALTH CENTER

- Topical petrolatum at least twice daily
- Add antibiotics if signs of infection
- Potent steroid-salicylic acid combination Refer to higher center if not responding in 6-8 weeks

SECONDARY CARE HOSPITAL AND TERTIARY CARE HOSPITAL

- In addition to those treatment prescribed at primary care
- Tar based applications/ steroid-salicylic acid with occlusion (if very thick plaques) for 2-4 weeks
- Phototherapy- Hand and foot NB UV-B/ PUVA soaks
- Systemic therapy - refer to treatment overview



ERYTHRODERMIC PSORIASIS

CLINICAL FEATURES

- Generalised erythema and scaling involving >90% of the BSA
- Triggered by withdrawal of systemic corticosteroids/ potent topical steroids or HIV infection
- Common D/D- dermatitis, drug reactions, pityriasis rubra pilaris, idiopathic erythroderma



PUSTULAR PSORIASIS

CLINICAL FEATURES

- Crops of localized or generalised sterile pustules and lakes of pus with surrounding erythema, often associated with fever
- In pregnancy- presents as impetigo herpetiformis, may lead to intrauterine growth retardation or still birth



GENERAL MANAGEMENT AT PRIMARY CARE

- Stabilize patient & treat secondary infection
- Maintain temperature/ fluid and electrolyte balance
- Admit if febrile & unstable vitals
- High protein diet
- Lab investigations: Complete Hemogram, Liver & Kidney Function test
- Refer to higher center for specific management

SPECIFIC MANAGEMENT

- Skin biopsy, if in doubt
- Methotrexate or Cyclosporine A
- Maintenance- Acitretin/ NB UVB/ PUVA
- If patient fails to respond, consider biologics

SPECIFIC MANAGEMENT

- Assess patient
- Take drug history (particularly Beta-lactams, Macrolides, Calcium channel blockers) to rule out acute generalized exanthematous pustulosis
- Generalized pustular psoriasis - admit the patient and follow general measures as for psoriatic erythroderma
- In addition to blood tests as listed previously, serum calcium (patients may have hypocalcemia) should also be estimated
- Acitretin/ Methotrexate/ Cyclosporine

PSORIASIS IS COMPLETELY TREATABLE BUT HAS A CHRONIC COURSE

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.